News
Bristol Myers Squibb And Cellares Announced A Worldwide Capacity Reservation And Supply Agreement For The Manufacture Of CAR T Cell Therapies In A Transaction Valued Up To $380M In Upfront And Milestone Payments
22 Apr 24
Biotech, Large Cap, News, Health Care, Contracts, General
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
21 Apr 24
Analyst Color, Equities, News, Top Stories, Tech, Trading Ideas
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics
19 Apr 24
Options, Markets
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
19 Apr 24
Biotech, Large Cap, News, Penny Stocks, Health Care, FDA, General
Wells Fargo Maintains Equal-Weight on Bristol-Myers Squibb, Raises Price Target to $52
18 Apr 24
News, Price Target, Analyst Ratings
Market Whales and Their Recent Bets on BMY Options
15 Apr 24
Options, Markets
Small-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom
12 Apr 24
Analyst Color, Biotech, Equities, News, Health Care, Price Target, Reiteration, Analyst Ratings, Movers, Trading Ideas, General
Peering Into Bristol-Myers Squibb's Recent Short Interest
12 Apr 24
Short Sellers, Short Ideas, Trading Ideas
This Is What Whales Are Betting On Bristol-Myers Squibb
11 Apr 24
Options, Markets
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
10 Apr 24
News, Penny Stocks, Markets, Trading Ideas
Bristol Myers Squibb's Acquired Adagrasib Combo Therapy May Benefit Colorectal Cancer Patients With Certain Mutation
8 Apr 24
Biotech, Large Cap, News, Health Care, General
Bristol Myers Squibb Announces KRAZATI In Combination With Cetuximab Demonstrates Clinically Meaningful Activity As A Targeted Treatment Option For Patients With Previously Treated KRAS G12C-Mutated Locally Advanced Or Metastatic Colorectal Cancer
8 Apr 24
Biotech, News, General
Bristol Myers' $14B Bet On Schizophrenia - Drug Cuts Symptoms Without Common Side Effect Of Weight Gain Associated With Other Antipsychotics
8 Apr 24
Biotech, Large Cap, News, Health Care, General
Reported Saturday, Bristol Myers Squibb Presented New Interim Long-Term Efficacy Data From The EMERGENT-4 Trial Evaluating Karxt In Schizophrenia At The 2024 Annual Congress Of The SIRS
8 Apr 24
News
FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer
5 Apr 24
Biotech, Large Cap, News, Health Care, FDA, General
U.S. FDA Approves Bristol Myers Squibb And 2seventy bio's Abecma For Triple-Class Exposed Relapsed Or Refractory Multiple Myeloma After Two Prior Lines Of Therapy; Abecma Tripled Progression-Free Survival Compared To Standard Regimens In The Phase 3 KarMMa-3 trial, With A 51% Reduction In Risk Of Disease Progression Or Death And A Well-Established Safety Profile
5 Apr 24
Biotech, News, FDA, General
Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
4 Apr 24
News, Penny Stocks, Small Cap, Markets, Trading Ideas
Standard BioTools Announces Multi-Year Strategic Engagement With Bristol Myers Squibb For Use Of The SomaScan Platform For Translational Medicine Research Through 2026
3 Apr 24
News, Contracts
Reported Earlier, European Commission Expands Approval Of Bristol Myers Squibb's Reblozyl® To Include First-Line Treatment Of Transfusion-Dependent Anemia In Adults With Lower-Risk Myelodysplastic Syndromes
3 Apr 24
News
One Good, One Bad News For Bristol Myers Squibb's Marketed Drugs: Details
1 Apr 24
Biotech, Equities, Large Cap, News, Health Care, General
Press releases
Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty
19 Apr 24
News, Press Releases
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
18 Apr 24
News, Press Releases
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest
17 Apr 24
News, Press Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
12 Apr 24
Press Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
8 Apr 24
News, Legal, Press Releases
KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
8 Apr 24
Press Releases
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
6 Apr 24
Press Releases
Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
6 Apr 24
Press Releases
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
5 Apr 24
Press Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
4 Apr 24
Press Releases
European Commission Expands Approval of Bristol Myers Squibb's Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
2 Apr 24
Press Releases
Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals
2 Apr 24
Press Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
31 Mar 24
News, Legal, Press Releases
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
28 Mar 24
Earnings, Press Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
27 Mar 24
Press Releases
Actinium Pharmaceuticals (ATNM) Spearheading the Future of Oncology with Iomab-ACT's Innovative Clinical Trial
27 Mar 24
News, Press Releases
Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave
26 Mar 24
News, Press Releases
Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio
25 Mar 24
Press Releases
FDA Approves Vertex Pharmaceuticals (NASDAQ:VRTX) VX-407 for Phase I Study in Groundbreaking Move Against Polycystic Kidney Disease"
25 Mar 24
News, Press Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
23 Mar 24
News, Legal, Press Releases